Domain Therapeutics and Ono Sign Collaboration Agreement

Domain Therapeutics S.A. has announced that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) have signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).

Under the agreement, Ono will provide Domain Therapeutics with an upfront payment, pay research funding for the collaborative research programs and success-based milestones on the research and development progress, as well as royalties on sales of the products.

Domain Therapeutics will apply DTect-All™, its proprietary GPCR drug discovery platform, and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono.

Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.

“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with pharma partners on integrated projects, from target to drug candidate,” said Pascal Neuville, CEO of Domain Therapeutics.

Neuville continued, “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”
 
Kazuhito Kawabata, Ph.D., member of the board of directors, executive officer and executive director, discovery and research of Ono said: “We highly appreciate Domain Therapeutics’ DTect-All™ technology and strongly believe that the company is the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs. We are expecting that innovative drugs will be created through this collaboration.”